Cetuximab and radiation for primary and recurrent squamous cell carcinoma of the head and neck (SCCHN) in the elderly and multi-morbid patient: A single-centre experience

Head and Neck Oncology

Volumn 2, Issue 1, 2010, Pages

  Jensen, Alexandra D ^a   Bergmann, Zazie P ^a   Garcia Huttenlocher, Helena ^b   Freier, Kolja ^a   Debus, Jürgen ^a   Münter, Marc W ^a  

^a Dept of Radiation Oncology INF ^*  (Germany)

^b AGAPLESION MARKUS KRANKENHAUS   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CETUXIMAB; ANTINEOPLASTIC AGENT; MONOCLONAL ANTIBODY;

ACNE; ADULT; AGED; ALLERGIC REACTION; ARTICLE; CANCER RADIOTHERAPY; CANCER SURVIVAL; COMORBIDITY; CONTROLLED STUDY; DRUG RESPONSE; DRUG WITHDRAWAL; ELDERLY CARE; FOLLOW UP; HEAD AND NECK CARCINOMA; HUMAN; MAJOR CLINICAL STUDY; MULTIPLE CYCLE TREATMENT; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RADIATION RESPONSE; RADIOIMMUNOTHERAPY; RECURRENT CANCER; SQUAMOUS CELL CARCINOMA; SURVIVAL TIME; TREATMENT RESPONSE; CARCINOMA; EVALUATION; FEMALE; HEAD AND NECK TUMOR; MALE; METASTASIS; METHODOLOGY; MIDDLE AGED; MULTIMODALITY CANCER THERAPY; PATHOLOGY; RECURRENT DISEASE; RETROSPECTIVE STUDY; TREATMENT OUTCOME;

ADULT; AGED; AGED, 80 AND OVER; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; CARCINOMA; COMBINED MODALITY THERAPY; COMORBIDITY; FEMALE; HEAD AND NECK NEOPLASMS; HUMANS; MALE; MIDDLE AGED; NEOPLASM METASTASIS; NEOPLASMS, SQUAMOUS CELL; RADIOIMMUNOTHERAPY; RECURRENCE; RETROSPECTIVE STUDIES; TREATMENT OUTCOME;

EID: 78649318588     PISSN: None     EISSN: 17583284     Source Type: Journal    
DOI: 10.1186/1758-3284-2-34     Document Type: Article

References (40)

1. Meta-analysis of chemotherapy in head and neck cancer (MACH-NC): an update on 93 randomised trials and 17,346 patients. JP Pignon A le Maitre E Maillard J Bourhis, Radiother Oncol 2009 92 4 14 10.1016/j.radonc.2009.04.014 19446902
2. Meta-analysis of chemotherapy in head and neck cancer (MACH-NC): an update. JP Pignon A le Maitre J Bourhis, et al. Int J Radiat Oncol Biol Phys 2007 69 112 114 17848275
3. Chemotherapy added to locoregional treatment for head and neck squamous-cell carcinoma: three meta-analyses of updated individual data. JP Pingnon J Bourhis C Domenge L Designe, et al. Lancet 2000 355 949 955 10768432
4. Chemoradiotherapy versus radiotherapy in patients with advanced nasopharyngeal cancer: phase III randomized Intergroup study 0099. M Al-Sarraf M LeBlanc PG Giri KK Fu J Cooper T Vuong, et al. J Clin Oncol 1998 16 1310 1317 9552031
5. Chemotherapy in locally advanced nasopharyngeal carcinoma: an individual patient data meta-analysis of eight randomized trials in 1753 patient. B Baujat H Audry J Bourhis ATC Chan H Onat DTT Chua, et al. Inf J Radiat Oncol boil Phys 2006 64 47 56 10.1016/j.ijrobp.2005.06.037 (Pubitemid 41831208)
6. Concurrent chemotherapy and radiotherapy for organ preservation in advanced laryngeal cancer. AA Forastiere H Goepfert M Maor TF Pajak R Weber W Morrison, et al. N Engl J Med 2003 349 2091 2098 10.1056/NEJMoa031317 14645636
7. Larynx preservation in pyriform sinus cancer: preliminary results of a European Organization for Research and Treatment of Cancer Phase III trial. JL Lefebvre D Chevalier B Luboinski A Kirkpatrick L Collette T Sahmoud, et al. J Natl Cancer Inst 1996 88 890 899 10.1093/jnci/88.13.890 8656441
8. Final results of the 94-01 French head and neck oncology and radiotherapy group randomized trial comparing radiotherapy alone with concomitant radiochemotherapy in advanced-stage oropharynx carcinoma. F Denis P Garaud E Bardet M Alfonsi C Sire T Germain, et al. J Clin Oncol 2004 22 69 76 10.1200/JCO.2004.08.021 14657228
9. An Intergroup phase III comparison of standard radiation therapy and two schedules of concurrent chemoradiotherapy in patients with unresectable squamous cell head and neck cancer. DJ Adelstein Y Li GL Adams H Wagner JA Kish JF Ensley, et al. J Clin Oncol 2003 21 92 98 10.1200/JCO.2003.01.008 12506176
10. A radiation therapy oncology group (RTOG) phase III randomized study to compare hyperfractionation and two variants of accelerated fractionation to standard fractionation radiotherapy for head and neck squamous cell carcinomas: first report of RTOG 9003. KK Fu TF Pajak A Trotti CU Jones SA Spencer TL Phillips, et al. Int J Radiat Oncol Biol Phys 2000 48 7 16 10.1016/S0360- 3016(00)00663-5 10924966
11. Hyperfractionated or accelerated radiotherapy in head and neck cancer: a meta-analysis. J Bourhis J Overgaard H Audry KK Ang M Saunders J Bernier, et al. Lancet 2006 368 843 854 10.1016/S0140-6736(06)69121-6 16950362 (Pubitemid 44292807)
12. Long term outcomes of RTOG 90-03:a comparison of hyperfractionation and two variants of accelerated fractionation to standard fractionation radiotherapy for head and neck squamous cell carcinoma. A Trotti KK Fu TF Pajak CU Jones SA Spencer TL Phillips, et al. Int J Radiat Oncol Biol Phys 2005 63 70
13. Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck. JA Bonner PM Harari J Giralt N Azarnia DM Shin RB Cohen, et al. N Engl J Med 2006 354 567 578 10.1056/NEJMoa053422 16467544
14. Radiotherapy plus cetuximab for locoregionally advanced head and neck cancer: 5-year survival data from a phase 3 randomised trial, and relation between cetuximab-induced rash and survival. JA Bonner PM Harari J Giralt RB Cohen CU Jones RK Sur, et al. Lancet Oncol 2010 11 21 28 10.1016/S1470-2045(09) 70311-0 19897418
15. Quality of life in head and neck cancer patients after treatment with high-dose radiotherapy alone or in combination with cetuximab. D Curran J Giralt PM Harari KK Ang RB Cohen MS Kies, et al. J Clin Oncol 2007 25 2191 2197 10.1200/JCO.2006.08.8005 17538164
16. Locoregionally advanced head and neck cancer treated with primary radiotherapy: a comparison of the addition of cetucimab or chemotherapy and the impact of protocol treatment. JJ Caudell SM Sawrie SA Spencer RA Desmoid WR Carroll GE Peters, et al. Int J Radiat Oncol Biol Phys 2008 71 676 681 10.1016/j.ijrobp.2007.10.040 18355979
17. Cetuximab combined with radiotherapy: an alternative to chemoradiotherapy for patients with locally advanced squamous cell carcinomas of the head and neck? J Bernier D Schneider, Eur J Cancer 2007 43 35 45 10.1016/j.ejca.2006.08. 035 17098420
18. Should Cetuximab replace cisplatin in head and neck cancer? K Rowan, J Natl Cancer Inst 2010 102 74 75 10.1093/jnci/djp531 20054019
19. Treatment of head and neck cancer in the elderly: European Consensus (panel 6) at the EUFOS congress in Vienna 2007. R Grenman D Chevalier V Gregoire W Myers S Rogers, Eur Arch Otorhinolaryngol 2010
20. Patterns of care in elderly head-and-neck cancer radiation oncology patients: a single-center cohort study. SH Huang B O'Sullivan J Waldron G Lockwood A Bayley J Kim B Cummings, et al. Int J Radiat Oncol Biol Phys 2010
21. Propsal for the delineation of the nodal CTV in the node-positive and the post-operative neck. V Gregoire A Eisbruch M Hamoir P Levendag, Radiother Oncol 2006 79 15 20 10.1016/j.radonc.2006.03.009 16616387
22. Rotterdam and Brussels CT-based neck nodal delineation compared with the surgical levels as defined by the American academy of otolaryngology-head and neck surgery. P Levendag M Braaksma E Coche P Van der Est M Hamoir K Muller, et al. Int J Radiat Oncol Biol Phys 2004 58 113 123 10.1016/S0360-3016(03)01453-6 14697428
23. A population-based atlas and clinical target volume for the head-and-neck lymph nodes. I Poon N Fischbein N Lee P Akazawa P Xia J Quivey, et al. Int J Radiat Oncol Biol Phys 2004 59 1301 1311 10.1016/j.ijrobp.2004.01.038 15275713
24. Randomized trial of postoperative reirradiation combined with chemotherapy after salvage surgery compared with salvage surgery alone in head and neck carcinoma. F Janot D de Raucourt E Benhamou C Ferron G Dolivet R Bensadoun, et al. J Clin Oncol 2008 26 5518 5523 10.1200/JCO.2007.15.0102 18936479
25. New guidelines to evaluate the response to treatment in solid tumors. P Therasse SG Arbuck EA Eisenhauer J Wanders RA Kaplan L Rubinstein, et al. J Natl Cancer Inst 2000 92 205 216 10.1093/jnci/92.3.205 10655437 (Pubitemid 30099779)
26. Nonparametric estimation from incomplete observations. EL Kaplan P Meier, J Am Stat Ass 1958 53 457 481 10.2307/2281868
27. Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer. MR Posner DM Hershock CR Blajman E Mickiewicz E Winquist V Gorbounova S Tjulandin DM Shin K Cullen TJ Ervin BA Murphy LE Raez RB Cohen M Spaulding RB Tishler B Roth C Viroglio Rdel V Venkatesan I Romanov S Agarwala KW Harter M Dugan A Cmelak AM Markoe PW Read L Steinbrenner AD Colevas CM Norris Jr RI Haddad TAX 324 Study Group, N Engl J Med 2007 357 1705 15 10.1056/NEJMoa070956 17960013
28. Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer. JB Vermorken E Remenar C van Herpen T Gorlia R Mesia M Degardin JS Stewart S Jelic J Betka JH Preiss D van den Weyngaert A Awada D Cupissol HR Kienzer A Rey I Desaunois J Bernier JL Lefebvre EORTC 24971/TAX 323 Study Group, N Engl J Med 2007 357 1695 704 10.1056/NEJMoa071028 17960012
29. Intensified hyperfractionated accelerated radiotherapy limits the additional benefit of simultaneous chemotherapy-results of a multicentric randomized German trial in advanced head-and-neck cancer. S Staar V Rudat H Stuetzer A Dietz P Volling M Schroeder, et al. Int J Radiat Oncol Biol Phys 2001 50 1161 1171 10.1016/S0360-3016(01)01544-9 11483325
30. Recursive partitioning analysis of 2105 patients treated in Radiation Therapy Oncology Group studies of head and neck cancer. JS Cooper NC Farnan SO Asbell M Rotman V Marcial KK Fu, et al. Cancer 1996 77 1905 1911 10.1002/(SICI)1097-0142(19960501)77:9<1905::AID-CNCR22>3.0.CO;2-2 8646692
31. Prognostic factors in oropharyngeal cancer - analysis of 627 cases receiving definitive radiotherapy. JP Agarwal I Mallick R Bhutani S Ghosh-Laskar T Gupta A Budrukkar, et al. Acta Oncol 2009 48 1026 1033 10.1080/ 02841860902845839 19363712
32. Pretreatment quality of life predicts for locoregional control in head and neck cancer patients: a radiation therapy oncology group analysis. F Siddiqui TF Pajak D Watkins-Bruner AA Konski JC Coyne CK Gwede, et al. Int J Radiat Oncol Biol Phys 2008 70 353 360 10.1016/j.ijrobp.2007.06.024 17889449
33. The better performance status, the better outcome: laryngeal carcinoma treated with definitive radiotherapy. V Yurut-Caloglu M Caloglu FN Turan K Ibis H Karagol Z Kocak, et al. J Otolaryngol Head neck Surg 2008 37 799 806 19128707
34. Final results of the 94-01 French head and neck oncology and radiotherapy group randomized trial comparing radiotherapy alone with concomitant radiochemotherapy in advanced-stage oropharynx carcinoma. F Denis P Garaud E Bardet M Alfonsi C Sire T Germain, et al. J Clin Oncol 2004 22 69 76 10.1200/JCO.2004.08.021 14657228
35. Long-term outcome of concurrent chemotherapy and reirradiation for recurrent and second primary head-and-neck squamous cell carcinoma. JK Salama EE Vokes SJ Chmura MT Milano JK Kao KM Stenson, et al. Int J Radiat Oncol Biol Phys 2006 64 382 391 10.1016/j.ijrobp.2005.07.005 16213104
36. Salvage re-irradiation for recurrent head and neck cancer. N Lee K Chan JE Bekelman J Zhung J Mechalakos A Narayana, et al. J Radiat Oncol Biol Phys 2007 68 731 740 10.1016/j.ijrobp.2006.12.055 (Pubitemid 46818729)
37. Full-dose reirradiation for unresectable head and neck carcinoma: experience at the Gustave-Roussy Institute in a series of 169 patients. R De Crevoisier J Bourhis C Domenge P Wibault S Koscielny A Lusinchi, et al. J Clin Oncol 1998 16 3556 3562 9817275
38. IMRT reirradiation of head and neck cancer - disease control and morbidity outcomes. EP Sulman DL Schwartz TT Le KK Ang WH Morrison DI Rosenthal, et al. Int J Radiat Oncol Biol Phys 73 399 409 18556144
39. Fractionated stereotactic radiotherapy as reirradiation for locally recurrent head and neck cancer. KW Roh JJ Jang MS Kim DI Sun BS Kim SL Jung, et al. Int J Radiat Oncol Biol Phys 2009 74 1348 1355 10.1016/j.ijrobp.2008.10.013 19117695
40. Higher dose per fraction and shorter overall treatment time using intensity-modulated radiation therapy versus conventional radiation therapy with concurrent carboplatin and 5-fluorouracil for locally advanced oropharyngeal carcinoma: a comparison of toxicity and efficacy. S Clavel D Nguyen P Despres B Fortin G Coulombe D Donath, et al. J Clin Oncol 2009 27 15s 10.1200/JCO.2008.21. 7695